Moreover, data form the Long-term Intervention with Pravastatin in Ischemic Heart Disease (LIPID) trial, collected from 7101 patients with a history of ACS 3–36 months before recruitment [15], showed that BNP >50.29 pg/mL doubled the risk of a future HF event over a five-year follow-up period. This evidence concerns the gene NPPB and coronary artery disorder.